View Item 

Show simple item record

Antiviral drug-resistant HBV: Standardization of nomenclature and assays and recommendations for management

dc.contributor.authorLok, Anna Suk-Fongen_US
dc.contributor.authorZoulim, Fabienen_US
dc.contributor.authorLocarnini, Stephenen_US
dc.contributor.authorBartholomeusz, Angelineen_US
dc.contributor.authorGhany, Marc G.en_US
dc.contributor.authorPawlotsky, Jean-Michelen_US
dc.contributor.authorLiaw, Yun-Fanen_US
dc.contributor.authorMizokami, Masashien_US
dc.contributor.authorKuiken, Carlaen_US
dc.date.accessioned2007-09-20T18:44:27Z
dc.date.available2008-09-08T14:25:12Zen_US
dc.date.issued2007-07en_US
dc.identifier.citationLok, Anna S.; Zoulim, Fabien; Locarnini, Stephen; Bartholomeusz, Angeline; Ghany, Marc G.; Pawlotsky, Jean-Michel; Liaw, Yun-Fan; Mizokami, Masashi; Kuiken, Carla (2007)."Antiviral drug-resistant HBV: Standardization of nomenclature and assays and recommendations for management Potential conflict of interest: Dr. Lok receives research support and serves on advisory board of GlaxoSmithKline, Gilead, Bristol Myers Squibb, Idenix, Roche Molecular Diagnostics and Innogenetics. Dr. Zoulim serves on advisory board of Gilead, Idenix, Bristol Myers Squibb, Innogenetics and receives research support from bioMerieux. Dr. Locarnini receives research support and serves on advisory board of Gilead Sciences, Bristol-Myers Squibb, Pharmasset, LG Sciences, Innogenetics and Evivar Pty Ltd. Dr. Bartholomeusz is a Consultant to Evivar Medical Pty Ltd. Dr. Pawlotsky receives research support and/or serves on advisory board of GlaxoSmithKline, Gilead, Bristol-Myers Squibb, Idenix and Novartis. Dr. Liaw receives research support and serves on advisory board and speaker bureau of Roche, Bristol-Myers Squibb, GlaxoSmithKline, and Idenix. ." Hepatology 46(1): 254-265. <http://hdl.handle.net/2027.42/56065>en_US
dc.identifier.issn0270-9139en_US
dc.identifier.issn1527-3350en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/56065
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=17596850&dopt=citationen_US
dc.description.abstractSubstantial advances have been made in the treatment of chronic hepatitis B in the past decade. Approved treatments for chronic hepatitis B include 2 formulations of interferon and 4 nucleos(t)ide analogues (NAs). Sustained viral suppression is rarely achieved after withdrawal of a 48-week course of NA therapy, necessitating long, and in many cases, indefinite treatment with increasing risk of development of drug resistance. Antiviral resistance and poor adherence are the most important factors in treatment failure of hepatitis B. Thus, there is a need to standardize nomenclature relating to hepatitis B antiviral resistance, and to define genotypic, phenotypic, and clinical resistance to NA therapy. (H EPATOLOGY 2007;46:254–265.)en_US
dc.format.extent239679 bytes
dc.format.extent3118 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherWiley Subscription Services, Inc., A Wiley Companyen_US
dc.subject.otherLife and Medical Sciencesen_US
dc.subject.otherHepatologyen_US
dc.titleAntiviral drug-resistant HBV: Standardization of nomenclature and assays and recommendations for managementen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelInternal Medicine and Specialtiesen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDivision of Gastroenterology, University of Michigan, Ann Arbor, MI ; fax: 734-936-7392 ; Division of Gastroenterology, University of Michigan Health System, 3912 Taubman Center, Ann Arbor, MI 48109-0362en_US
dc.contributor.affiliationotherINSERM, U271; UniversitÉ Lyon I; Hospices Civils de Lyon, Lyon, Franceen_US
dc.contributor.affiliationotherVictorian Infectious Diseases Reference Laboratory, North Melbourne, Victoria, Australiaen_US
dc.contributor.affiliationotherVictorian Infectious Diseases Reference Laboratory, North Melbourne, Victoria, Australiaen_US
dc.contributor.affiliationotherLiver Diseases Branch, National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MDen_US
dc.contributor.affiliationotherFrench National Reference Center for Viral Hepatitis B, C and delta, Department of Virology and INSERM U841, Hopital Henri Mondor, Universite Paris 12, Creteil, Franceen_US
dc.contributor.affiliationotherLiver Research Unit, Chang Gung University and Memorial Hospital, Taipei, Taiwanen_US
dc.contributor.affiliationotherDepartment of Clinical Molecular Informative Medicine, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japanen_US
dc.contributor.affiliationotherTheoretical Biology and Biophysics Group (T-10), Los Alamos National Laboratory, Los Alamos, NMen_US
dc.identifier.pmid17596850en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/56065/1/21698_ftp.pdfen_US
dc.identifier.doihttp://dx.doi.org/10.1002/hep.21698en_US
dc.identifier.sourceHepatologyen_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
21698_ftp.pdf
Size:
234.0KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.